Lifecore Biomedical Debt to Equity

Lifecore Biomedical (LFCR) currently reports a debt-to-equity ratio of 9.96. That is above the Materials sector average of 0.9. Use the charts on this page to explore Lifecore Biomedical's debt-to-equity ratio history and peer comparisons.

Lifecore Biomedical's debt-to-equity ratio of 9.96 is higher than the Materials sector average of 0.9. That is roughly 1003.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Lifecore Biomedical's market price to a fundamental measure such as earnings, sales, or book value. At 9.96, LFCR can look expensive or cheap only in context — versus its own history, growth rate, and Materials peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 9.96, then check the historical chart for trend and the peer comparison chart for relative positioning. The Materials average is 0.9. From there, open related valuation or income-statement pages for Lifecore Biomedical, and consider following LFCR for alerts when major investors trade the stock.

Lifecore Biomedical is classified in the Materials sector. On debt-to-equity ratio, it currently shows 9.96 versus a sector average near 0.9. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Materials are usually more informative than comparing LFCR with unrelated industries.